These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16154482)

  • 1. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.
    Maglio D; Kuti JL; Nicolau DP
    Clin Ther; 2005 Jul; 27(7):1032-42. PubMed ID: 16154482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
    Ellis JM; Kuti JL; Nicolau DP
    Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.
    Masterton RG; Kuti JL; Turner PJ; Nicolau DP
    J Antimicrob Chemother; 2005 Jan; 55(1):71-7. PubMed ID: 15574471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK; Kuti JL; Nicolau DP
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
    Kotapati S; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.
    Kiffer CR; Mendes C; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2004 Jun; 49(2):109-16. PubMed ID: 15183860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
    Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
    Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.
    Crandon JL; Kuti JL; Jones RN; Nicolau DP
    Ann Pharmacother; 2009 Feb; 43(2):220-7. PubMed ID: 19193582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.
    DeRyke CA; Kuti JL; Nicolau DP
    Pharmacotherapy; 2007 Mar; 27(3):333-42. PubMed ID: 17316145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.
    Kuti JL; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2464-70. PubMed ID: 15215095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
    Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB
    J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China.
    Wang C; Bai Y; Li R; Shen C; Zhang J
    Diagn Microbiol Infect Dis; 2020 Jun; 97(2):115039. PubMed ID: 32253072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling.
    Eagye KJ; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2007 Apr; 8(2):215-26. PubMed ID: 17437367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
    Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
    J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004.
    Eagye KJ; Nicolau DP; Lockhart SR; Quinn JP; Doern GV; Gallagher G; Abramson MA
    Ann Clin Microbiol Antimicrob; 2007 Oct; 6():11. PubMed ID: 17908321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program.
    Koomanachai P; Crandon JL; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2009 Apr; 33(4):348-53. PubMed ID: 19091515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.